Table 2 Short-term post-operative outcomes
Outcome | Pre-op levosimendan (n = 40) | No-levosimendan (n = 22) | Total (n = 62) | P value |
|---|---|---|---|---|
Additional surgical procedures | 10 (25) | 3 (13.6) | 13 (21) | 0.34 |
Cardiopulmonary bypass time—minutes | 93 (83.75–115.25) | 105 (87.5–127.5) | 97.5 (84.25–116.75) | 0.39 |
Post-op ventilation support time—hours | 24 (22–29.75) | 27 (22–56.75) | 25 (22–48) | 0.19 |
Maximal CVP—mmHg | 22 (18–26) | 23 (19–26) | 22 (19–26) | 0.58 |
Post-op inotrope support time—hours | 51 (19–88) | 72 (18–125) | 60 (19–112) | 0.41 |
Inotropic support > 14 days | 1 (2.5) | 1 (4.5) | 2 (3.2) | 0.66 |
RVF | 3 (7.5) | 3 (13.6) | 6 (9.6) | 0.43 |
Echocardiography at discharge | ||||
Enlarged RV | 14 (35) | 9 (40.9) | 23 (37.1) | > 0.999 |
RV function | 0.59 | |||
Normal | 7 (24.1) | 5 (29.4) | 12 (19.4) | |
Mild reduction | 4 (13.8) | 4 (23.5) | 8 (12.9) | |
Moderate—severe reduction | 18 (62.1) | 8 (47.1) | 26 (41.9) | |
Laboratory at discharge | ||||
Creatinine—mg/dL | 0.77 (0.63–1.02) | 0.99 (0.76–1.09) | 0.87 (0.69–1.09) | 0.073 |
MDRD—mL/min/1.73 m2 | 96.3 (78.4–143.3) | 83.8 (74.7–111.2) | 95.7 (78.1–132.1) | 0.19 |
Bilirubin—mg/dL | 0.61 (0.44–0.9) | 0.68 (0.5–0.86) | 0.87 (0.69–1.09) | 0.39 |
Albumin—g/dL | 3 (2.8–3.2) | 2.9 (2.6–3.1) | 2.9 (2.7–3.2) | 0.31 |
Post-op Complications—Any | 15 (68.1) | 21 (52.5) | 36 (58) | 0.23 |
Total hospitalization length –days | 13 (9.25–23.5) | 16 (10.75–25.75) | 14 (10–24.25) | 0.53 |
ICU hospitalization length—days | 3 (2–5) | 4 (2–6) | 3.5 (2–6) | 0.44 |
Short term mortality | ||||
During hospitalization | 1 (2.5) | 1 (4.5) | 2 (3.2) | > 0.999 |
30 days | 0 (0%) | 1 (4.5%) | 1 (1.6) | 0.76 |